LBF20303PG05

LipidBank Top (トップ)

Fatty acid (脂肪酸)

Glycerolipid (グリセロ脂質)

Sphingolipid (スフィンゴ脂質)

Journals (雑誌一覧)

How to edit (ページの書き方)

Upper classes: LB LBF

IDs and Links
LipidBank	XPR1705
LipidMaps	LMFA03010142
CAS
KEGG	{{{KEGG}}}
KNApSAcK	{{{KNApSAcK}}}
mol	LBF20303PG05

Prostaglandin D3
Structural Information
Systematic Name	(9α,15S) -Dihydroxy-11-oxo-prosta- (5-cis,13-trans,17-cis) -trien-1-oic acid
Common Name	Prostaglandin D3 (9α,15S) -Dihydroxy-11-oxo-prosta- (5Z,13E,17Z) -trien-1-oic acid
Symbol
Formula	C20H30O5
Exact Mass	350.20932407
Average Mass	350.4492
SMILES	C(=CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)C(C[C@@H]1O)=O)CC
Physicochemical Information
Melting Point
Boiling Point
Density
Optical Rotation
Refractive Index
Solubility
Source	PGD3 is produced by the metabolism of EPA via the cyclooxygenase pathway. Kulkarni_PS et al.
Chemical Synthesis
Metabolism
Biological Activity	PGD3 has almost same ability to decrease systemic blood pressure in rats and to decrease intraocular pressure in rabbits. Bundy_GL et al. Goh_Y et al. Kulkarni_PS et al. However, it is 3 to 5 times more potent than PGD2 in the inhibition of ADP-induced human platelet aggregation.
Genetic Information
Note
Spectral Information
Mass Spectra
UV Spectra
IR Spectra
NMR Spectra
Other Spectra
Chromatograms

Reported Metabolites, References
Biospecies ID Compound Name Reference Comment n.a. LBF20303PG05 See above. Bundy_GL et al. 1983 n.a. LBF20303PG05 See above. Goh_Y et al. 1988 n.a. LBF20303PG05 See above. Herschman_HR 1996 n.a. LBF20303PG05 See above. Kulkarni_PS et al. 1987 n.a. LBF20303PG05 See above. Kulkarni_PS et al. 1985 n.a. LBF20303PG05 See above. Smith_WL et al. 1996